Navigation Links
Dawson James Initiates Research Coverage of Advanced Life Sciences

CHICAGO, Dec. 2, 2010 /PRNewswire/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that Dawson James Securities Inc., has initiated analyst research coverage of Advanced Life Sciences. The report highlights Restanza™ (cethromycin) as a promising late-stage antibacterial treatment for life-threatening pathogens.


A copy of the report can be found by clicking the following link or copying and pasting the link into your browser:

About Restanza

Restanza is a novel, once-a-day, oral antibiotic that is in late stage development for the treatment of adults with mild-to-moderate community acquired bacterial pneumonia ("CABP") and biodefense pathogens. It has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria associated with respiratory tract infections and appears to be effective against penicillin-, macrolide- and fluoroquinolone-resistant bacteria. Restanza's demonstrated potency and ability to overcome bacterial resistance may be due to its mechanism of action resulting in specificity for its bacterial target.

In addition to its utility in CABP, Restanza is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure and other high priority biodefense pathogens, including plague and tularemia. The FDA has designated Restanza as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, as well as for use in treating plague and tularemia, but the drug is not yet approved for these or any other indications.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia.

For more information, please visit us on the web at or follow us on twitter at

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment regarding future events. The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers. These and additional risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission.

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novus Scientific and Singapore Association of Plastic Surgeons (SAPS) Host the Inaugural Event of SOFTISSUE - The Issue of Soft Tissue, Featuring James J. Chao, M.D., FACS, Professor of Plastic Surgery and Orthopedic Surgery, University of Califor
2. Dr. Brian Boxer Wachler to be Honored With Olympic Gold Medal Bobsled Champion Steve Holcomb Alongside Apple CEO Steve Jobs, James Cameron, Dan Rather, Quincy Jones and Others at 2010 Vision Awards in Beverly Hills
3. James F. Szigethy Named Curemarks Director of New Product Development
4. Thoratec Presentation at Raymond James Conference to Be Webcast
5. Hill-Rom Announces Appointment of James R. Giertz to Board of Directors
6. AMD LASERS Names Dr. James Jesse as Medical Director
7. Dr. James F. Pingpank to Present at Leading Regional Therapies Conference
8. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
9. Additional Regional Medicare Carrier Initiates Coverage for Posterior Tibial Nerve Stimulation (PTNS) Delivered via Uroplastys UrgentĀ® PC Neuromodulation System
10. Pathfinder Initiates Minimally Invasive Surgical Navigation Study
11. NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD
Post Your Comments:
(Date:10/12/2015)... October 12, 2015 ... to grow at 7.2% CAGR, microscopy market ... rising focus on nanotechnology, technological advancements, and ... report available with ... . --> Complete report on ...
(Date:10/12/2015)...   Royal Philips (NYSE: PHG, AEX: PHIA), ... a collaboration with Genomic Health , Inc. (NASDAQ: ... diagnostic tests, to leverage Philips digital pathology tools in ... testing processes.    --> ... samples and plays a crucial role in the diagnosis ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: ... District of Delaware granted the Company,s ... Pharmaceuticals, Abbreviated New Drug Application (ANDA) No. 205299 to market ... (buprenorphine and naloxone) Sublingual Film (CIII) in the ... --> Since August 2013, Indivior has received Paragraph IV ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... 2015 , ... The American Society of Clinical Hypnosis (ASCH) ... and clinical training in a health care discipline. , Many practitioners claim ... losing weight, managing pain, or stopping smoking, etc. Frequently, extravagant statements and guarantees ...
(Date:10/12/2015)... ... October 12, 2015 , ... AcousticSheep LLC, creators of ... in honor of Breast Cancer Awareness Month. During the month of October, ... a SleepPhones® Classic product to a breast cancer patient at the Cleveland Clinic. ...
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... NFL football fans who are interested in having an opportunity to ... CLICK HERE to donate to Smile for a Lifetime (S4L) Foundation and gift ... all-inclusive trip to the 2016 NFL Super Bowl! , Donors contributing $20.00 or more between ...
(Date:10/12/2015)... , ... October 12, 2015 , ... The translation for ... seamless migration of complete ARIS installations into the Microsoft world. The ARIS models ... As Microsoft Visio® is very familiar for both IT and Office users it is ...
Breaking Medicine News(10 mins):